Authors: Barry, O.P.; Kazanietz, M.G.

Source: Current Drug Metabolism, Volume 7, Number 17, 1 November 2001 , pp. 1725-1744(20)

Publisher: Bentham Science Publishers

Abstract:

Recent years have seen extensive growth in the understanding of the role(s) of the various PKC isozymes and novel receptors for the phorbol ester tumor promoters. The PKC family of serine-threonine kinases is an important regulator of signaling cascades that control cell proliferation and death, and therefore represent targets for cancer therapy. While past interests have focused on PKC-selective inhibitors, more recently, intensive research has been underway for selective activators and inhibitors for each individual PKC isozyme. In the past few years a large number of PKC activators and inhibitors with potential as anticancer agents have been developed. A number of these compounds are already in Phase II clinical testing. As a new generation of cancer chemotherapeutic agents are designed, developed and put through a series of rigorous clinical trials, we can anticipate achieving exquisite control over PKC-mediated regulatory pathways, leading ultimately to a greater understanding of different cancers.

Keywords: Protein Kinase C; Phorbol Ester Receptors; Cancer Chemotherapy; PKC isozymes; non-kinase phorbol ester receptors; Diacylglycerols; PKC Inhibitors; PKC Binding Proteins; Indolocarbazoles; Bisindolylmaleimides

Document Type: Review article

DOI: http://dx.doi.org/10.2174/1381612013397041

Publication date: 2001-11-01

More about this publication?

• Current Pharmaceutical Design publishes timely in-depth reviews covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area. A Guest Editor who is an acknowledged authority in a therapeutic field has solicits for each issue comprehensive and timely reviews from leading researchers in the pharmaceutical industry and academia.
  
  Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design, including: medicinal chemistry, pharmacology, drug targets and disease mechanism.

Related content

• In this: publication
• By this: publisher
• In this Subject: Pharmacology
• By this author: Barry, O.P. ;  Kazanietz, M.G.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers